Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

RBC Capital Downgrades Agios Pharmaceuticals to Sector Perform, Lowers Price Target to $28

Author: Benzinga Newsdesk | November 20, 2025 09:56am
RBC Capital analyst Luca Issi downgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Outperform to Sector Perform and lowers the price target from $57 to $28.

Posted In: AGIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist